Background: Lung cancer is the leading cause of cancer-related morbidity and mortality worldwide. Patients with chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), are exposed to a higher risk of developing lung cancer. Chronic inflammation may play an important role in the lung carcinogenesis among those patients. The present study aimed at identifying candidate biomarker predicting lung cancer risk among patients with chronic respiratory diseases.
lung cancer is triggered. The emergency of genomics and clinical bioinformatics allows defining gene alterations during the process of carcinogenesis to further understand the relationship between chronic inflammation and the onset of lung cancer.
The myocyte enhancer factor 2 (MEF2) family of human transcription factors, consisting of four subtypes, MEF2-A, -B, -C and -D, have a diversity of functions in different tissues and have been implicated in numerous diseases. MEF2s play an important role in the activation of the genetic processes that control cell differentiation, proliferation, and apoptosis in a wide range of cell types [10] . It has been reported that MEF2 is correlated with lower physical activity in COPD patients [11] . Altered MEF2 activity has been revealed as driver of cancer development, including both hematological cancers and solid tumor. Recent study found that MEF2 genes might act as oncogenes in NSCLC [12] .
The present study is aimed to figure out candidate "communicator" between chronic inflammation and lung cancer and determine the potential regulatory mechanism. We highlight studies exploring the link between inflammation and cancer and discuss emerging biomarker for predicting risk of lung cancer among patients with chronic respiratory diseases.
Methods

Bioinformatics tools
We used "lung cancer" as the search keyword and "human" as organism to search for GSE datasets in Gene Expression Omnibus (GEO) online database. GSE datasets containing comparative gene expression profiling between lung cancer and non-cancer tissues, pathological definitions, and information of data normalizing methods were enrolled in the present study. Gene expression profiling data of each dataset were restored to original data, re-normalized with reference genes, and transformed to the ratio of expression data, and then integrated into one dataset. Genes with twofolds and more than twofolds up or down change in lung cancer subtypes were thought to be significantly differential genes, compared with noncancer tissues. All the differential genes were used in further bioinformatics analysis.
Cell culture
Human NSCLC cell line A549 cells, human bronchial epithelial cell line HBE cells, and human normal bronchial epithelial cell line BEAS-2B cells were obtained from Shanghai Institute for Biological Science. Cells were cultured in DMEM (high glucose, Hyclone, Logan, UT, USA), supplemented with 10% FBS (Hyclone, Logan, UT, USA), 100 U/ ml penicillin, and 100 μg/ml streptomycin at 37 °C in a 5% CO 2 , 95% air environment in humidified incubators.
Ion Torrent-based RNA-sequencing RNA extraction was performed using the TRIZOL ™ LS reagent (Invitrogen, Carlsbad, CA, USA). rRNA depletion was performed using the RiboMinus ™ Eukaryote System v2 (Ambion ® ) following standard protocols. First, total RNA was hybridized with biotinylated RiboMinus ™ Eukaryote Probe Mix v2. Next, the rRNA-probe complexes were removed from the total RNA by captured with streptavidin-conjugated RiboMinus ™ Magnetic Beads. The resulting rRNA-depleted RNA was concentrated and purified with Nucleic Acid Binding Beads. The cDNA libraries were barcoded using the ion total RNASeq Kit v2 (Ambion ® ) following standard protocols. RNA sequencing was performed on the Ion Proton ™ System (Life Technologies, Carlsbad, CA, USA). Data analysis was performed using Torrent Suite ™ Software 4.0 (Ion Torrent). Genes with twofolds and more than twofolds up or down change in LPS-stimulated A549 cells were thought to be significant, compared with the control group.
Quantitative real time polymerase chain reaction (qRT-PCR) analysis
RNA extraction was performed using the TRIZOL ™ LS reagent (Invitrogen, Carlsbad, CA, USA). cDNA was prepared using PrimeScript ® RT reagent Kit (Takara, Shiga, Japan) following standard protocols. qRT-PCR was performed using SYBR ® Premix Ex Taq ™ (Takara, Shiga, Japan) on the ABI 7000 PCR instrument (Eppendorf, Hamburg, Germany) with the following two-stage program parameters: 1 min at 95 °C and then 40 cycles of 5 s at 95 °C and 30 s at 60 °C. All samples were run in triplicate, and each group had six wells. Results were shown as relative target mRNA levels. The sequences of the primers used for this analysis are as follows:
MEF2A Forward, 5′-CCGACTGCCTACAACACTGA-3′, MEF2A Reverse, 5′-GATAACTGCCCTCCAGCAAC-3′; MEF2B Forward, 5′-AAGTTCGGGCTGATGAAGAA-3′, MEF2B Reverse, 5′-CATACTGGAAGAGGCGGTTG-3′; MEF2C Forward, 5′-CTGGCAACAGCAACACCTAC-3′, MEF2C Reverse, 5′-GAAGGCAGGGAGAGATTTG-3′; MEF2D Forward, 5′-CACCTGACAATCACCCACAC-3′, MEF2D Reverse, 5′-AGCATCACCATACAGCACGA-3′; GAPDH Forward, 5′-CCACCCATGGCAAATTCCATG GCA-3′, GAPDH Reverse, 5′-TCTACACGGCAGGTCAGGTC CACC-3′.
Western bolt analysis
Intracellular protein was extracted by radio immunoprecipitation assay lysis buffer. Protein samples (50 μg) were mixed with an equal volume of 5× sodium dodecyl sulfate buffer, boiled for 5 min, and then separated through 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels. Proteins were transferred to polyvinylidene fluoride membranes by electrophoretic transfer after electrophoresis. Membranes were blocked in 5% dry milk for 2 h, rinsed, and incubated with primary antibodies (diluted at their instructions) in TBS thrice at 4 °C overnight. Primary antibody was then removed by washing in TBS and labeled by incubating with 0.1 mg/ml peroxidase-labeled secondary antibodies (against mouse and rabbit) for 2 h. Following three washes in TBS, bands were visualized by ECL (Tanon, Shanghai, China) and exposed to X-ray film. The band densities were quantified with Image J. The results were presented as ratio of band density to total actin.
Small interfering RNA (siRNA) transfection
Three different sequences targeting MEF2D (Additional file 1: Table S1 ) were designed and provided by GenePharma (Shanghai, China). siRNA transfection was performed according to the manufacturer's protocol. Briefly, 1 μl Lipofectamine 2000 and 50 pmol each siRNA were mixed. Cells were then transfected with Lipofectamine/ siRNA complexes and incubated at 37 °C for 24 h. Transfection efficiency was evaluated by qRT-PCR and Western Blot analysis. Clones with optimized transfection were selected for stable transfection of MEF2D and used in the experiments.
Alive measurement of cell bio-behaviors
The cell bio-behaviors including total cell number, cell differentiation, and cell movement were dynamically measured through a Cell-IQ platform (Chip-Man Technologies, Tampere, Finland), equipped with a phase-contrast microscope (Nikon CFI Achromat phase contrast objective with ×10 magnification) and a camera (Nikon, Fukasawa, Japan 
Cell migration assay
In the Transwell assay (Corning Inc., Corning, NY, USA), cells were seeded in the upper chamber at the concentration of 5 × 10 5 /ml in serum-free medium, while medium containing 10% FBS was added to the lower chamber. Cells migrated through the permeable membrane at 48 h were fixed and stained with Giemsa, and then counted under microscope.
Cell proliferation assay
In the cell proliferation assay, cells were seeded in 96-well plates at the concentration of 1 × 10 4 /well and incubated with AR (40 ng/ml) for 24, 48 or 72 h at 37 °C with 5% CO 2 , after which 10 μl of the Cell Counting Kit-8 solution (Dojindo, Japan) was added to the medium. After 2-h incubation, the amount of orange formazan dye generated was determined by measuring the absorbance at 450 nm under microplate reader (Thermo Scientific, Carlsbad, CA, USA).
Statistical analysis
All values were expressed as mean ± SEM. Statistical analysis was performed using SPSS software (SPSS 20.0; SPSS Inc; Chicago, IL, USA). Values between lung cancer subtypes were analyzed with Students's t test and MannWhitney U test. Data were evaluated using ANOVA with LSD test for multiple comparisons and Students's t test between two groups. p < 0.05 was considered as statistical significant.
Results
Elevated MEF2D level in COPD patients with NSCLC
16 GSE datasets containing comparative gene expression profiles of lung cancer and non-cancer tissues, pathological definitions, and information of data normalizing methods were enrolled in the present study through clinical bioinformatics tools. There were totally 677 NSCLC, 9 LCC, 56 SCLC cases, and 590 non-cancer cases. In patients with NSCLC, the expressions of MEF2A and MEF2D were significantly higher, compared with noncancer tissues (Fig. 1a , p < 0.01 and 0.001, respectively). In patients with LCC or SCLC, the expressions of MEF2A were significantly lower, compared with non-cancer tissues (Fig. 1b, c , p < 0.01, and 0.001, respectively). The MEF2D levels were also decreased in patients with LCC or SCLC as compared with non-cancer tissues (Fig. 1b,  c) . Further data mining demonstrated significantly higher MEF2D level in COPD patients with NSCLC than that in smokers, patients with COPD and no NSCLC, or patients with NSCLC and no COPD, compared with healthy nonsmokers (Fig. 1d , p < 0.001).
Increased MEF2D expression inflammation-activated NSCLC cell line
We carried out Ion Torrent-based RNA-sequencing in a model of LPS-challenged NSCLC cell line A549. A549 Figure 2b showed the gene network associated with MEF2D.
MEF2D specifically up-regulated in inflammation-activated NSCLC cell line
We investigated MEF2s gene expression in different lung cell lines through qRT-PCR analysis. We found that LPS challenge significantly up-regulated the mRNA levels of MEF2D in NSCLC cell line A549 cells, as compared with those stimulated with vehicle, in accordance with the RNA-seq results (Fig. 3a) . The mRNA levels of MEF2D were also up-regulated in HBE cells after LPS stimulation, but the fold changes were lower than those in LPS-activated A549 cells (Fig. 3b) . As shown in Fig. 3c , levels of MEF2D were not significantly altered in BEAS-2B cells.
MEF2D expressions increased associated with the severity of inflammation
The mRNA expressions of MEF2D in LPS-stimulated A549 cells increased in a concentration-dependent pattern and reached to the highest level when LPS concentration was 1 μg/ml (Fig. 4a, p < 0.001) . LPSstimulated expression of MEF2D mRNA increased in a time-dependent pattern as well, and reached to the highest level at 24 h after LPS stimulation (Fig. 4b, p < 0.001) . The protein expressions of MEF2D also increased in a concentration-or time-dependent pattern after LPS stimulation, and reached to the highest level when LPS concentration was 1 μg/ml (Fig. 4c, p < 0. 01) or at 72 h after LPS stimulation (Fig. 4d, p < 0.01) , respectively, in accordance with the mRNA expressions.
MEF2D-deficiency impaired NSCLC cell bio-behaviors
We used the real-time cell monitoring system to investigate the effect of MEF2D on cell bio-behaviors. We found that MEF2D-deficiency significantly reduced the capacity of cell proliferation (Fig. 5a), differentiation (Fig. 5b) or movement ( was further investigated by Transwell assay. As shown in Fig. 5d1, d2 , MEF2D-knockdown A549 cells by siRNA had significantly impaired capacity of migration toward 10% FBS, compared with the control cells (p < 0.01). The role of MEF2D in A549 cells proliferation was further investigated by CCK-8 assay. As shown in Fig. 5e , capacity of cell proliferation was significantly reduced in MEF2D-knockdown A549 cells, compared with the control cells.
Extracellular signal-regulated protein kinase (ERK) inhibition reversed up-regulation of MEF2D in inflammation-activated NSCLC cell line
A549 cells respectively pretreated with ERK inhibitor PD98059 or PI3 K inhibitor LY290042 at doses of 10, 20 and 30 μM for 2 h were then challenged with vehicle or LPS at the concentration of 1 μg/ml for 48 h. Treatment with PD98509 significantly reversed LPS-induced upregulation of MEF2D (Fig. 6a , p < 0.05), while treatment with LY290042 did not alter the LPS-induced MEF2D expression significantly (Fig. 6b) .
Discussion
MEF2D, a transcription factor of the MEF2 family, is not only critical for myogenesis, but also plays an important role in regulating diverse developmental programs [13] . It has been implicated that MEF2D is involved in different types of malignancies, including acute lymphoblastic leukemia, hepatocellular carcinoma and osteosarcoma [14] [15] [16] [17] [18] . Recently, MEF2D has been reported to promote the growth of lung cancer [19] . In this study, we found that MEF2D was overexpressed in clinical NSCLC tissues. Further data mining showed significantly higher MEF2D level in COPD patients with NSCLC than that in smokers, patients with COPD and no NSCLC, or patients with NSCLC and no COPD. Growing evidence has shown that patients with chronic respiratory conditions such as COPD exhibit a significantly higher risk of lung cancer [8] . It is reported that 50-90% lung cancer patients have coexisting COPD [20] . Chronic inflammation associated with COPD seems to be a critical player in lung cancer development and prognosis [21, 22] , related to 15-20% of cancer deaths [23] , while little is known about the underlying mechanism. The results prompted us to further speculate whether MEF2D might act as a communicator between inflammation and lung cancer.
The present study adopted an in vitro model based on LPS-stimulated A549 to explore the underlying link between inflammation and lung cancer. Our data showed that MEF2D expression was significantly elevated in inflammation-activated NSCLC cell line A549 through Ion Torrent-based RNA-sequencing analysis, as were genes associated with MEF2D network. LPS challenge specifically up-regulated the MEF2D mRNA expression in A549 significantly rather than in bronchial epithelial cell lines HBE or BEAS-2B cells. Our data also demonstrated that LPS challenge up-regulated the mRNA or protein levels of MEF2D in A549 in a LPS-concentration dependent and time dependent manner. It seems that the influencing roles of inflammation in the expression of MEF2D are related with the severities.
Diverse calcium-dependent signaling pathways have been revealed as regulators of MEF2 activity, including calcium/calmodulin-dependent protein kinase (CaMK) signaling, calcineurin signaling, and mitogen-activated protein kinase (MAPK) signaling [10] . MAPKs are mainly divided into three signaling cascades: ERK, p38 kinase and c-jun N-terminal kinase (JNK) pathways. In accordance with the previous study [24] , we found that the ERK signaling pathway may play the critical and dependent role in the mechanism of MEF2D production of A549, evidenced by the finding that the over-production of MEF2D by LPS-challenge was prevented by ERK inhibitor. Further study is needed to demonstrate MEF2D targeted genes after inflammation challenge.
Inflammation plays multifaceted roles in all stages of tumorigenesis, including malignant transformation, tumor initiation to invasion, and metastasis of established tumor [25] . Cancer-related inflammatory microenvironment, mainly composed of inflammatory cells and mediators, has been accepted as a significant factor through which inflammation contributes to the multiple capabilities of cancer [26] . Our previous study reported that inflammation-activated lung cells could act as the initiators and/or secondary sources of the development of cancer microenvironment [27] . Consistent with our previous study, we provide further evidence that inflammatory conditions might contribute to remodeling of the cancer microenvironment through up-regulating MEF2D expression.
During a host response to bacterial pathogens, activation of MEF2 by p38 kinase pathway has been related to expression of pro-inflammatory cytokines [28] . In primary human T lymphocytes, MEF2D is required for the synthesis of IL-2 mRNA and secretion of IL-2 in response to T cell receptor stimulation [29] . MEF2 participates in the regulation of B lymphocyte proliferation and survival after B cell receptor stimulation [30] . MEF2D is identified as an important regulator of IL-10 gene expression [31] . Given the critical roles of MEF2 in regulation of inflammatory responses, up-regulation of MEF2D might lead to remodeling of cancer microenvironment through lymphocytes recruitment or mediators production during inflammatory condition. Further in vitro study is needed to clarify the underlying mechanism.
MEF2D has been reported to serve as oncogene in B cell acute lymphoblastic leukemia [15] and hepatocellular carcinoma [16, [32] [33] [34] through promotion of colony formation and proliferation, inhibition of apoptosis, epithelial-mesenchymal transition and invasiveness. MEF2D also acts as tumor suppressor in liposarcoma, leiomyosarcoma [35] and rhabdomyosarcoma [36, 37] through promotion of cell proliferation and anchorage independent growth and inhibition of differentiation. Consistent with the previous studies, we found that MEF2D played a critical role in bio-behaviors of NSCLC cells. While targeted knockdown of MEF2D gene via siRNA significantly impaired the capacity of cancer cell differentiation, proliferation or movement. Up-regulation of MEF2D during Briefly, inflammatory conditions led to increased MEF2D expression, which might further contribute to the development of malignancy through influencing cancer microenvironment and cell bio-behaviors. As far as we know, this is the first study focused on MEF2D as a "communicator" between chronic inflammation and lung cancer. MEF2D might be a potential biomarker for patients with chronic respiratory diseases, such as COPD, who are at risk of developing lung cancer.
However, the present study has some limits. Although we adopted an in vitro model based on LPS-stimulated A549 to mimic inflammatory conditions of airways, there are still differences between chronic airway inflammation in vivo and the in vitro model. Much more remains to be learned about the regulatory mechanism of MEF2D to communicate between chronic inflammation and lung cancer.
Conclusions
Taken together, the present study demonstrated significantly higher MEF2D level in COPD patients with NSCLC than that in smokers, patients with COPD and no NSCLC, or patients with NSCLC and no COPD. Inflammation challenge increased MEF2D expression in A549, associated with the severity of inflammation, while ERK inhibition could reverse the up-regulation of MEF2D. MEF2D played a critical role in NSCLC cell differentiation, proliferation, or movement. MEF2D might contribute to the development of lung cancer through influencing cancer microenvironment and cell bio-behaviors during inflammatory conditions. MEF2D provides a cross-talk between chronic inflammation and lung caner. MEF2D could be a potential biomarker predicting risk of lung cancer among patient with chronic respiratory diseases. More studies are still needed to explore the further mechanism between chronic inflammation and lung cancer.
